Norbrook Laboratories has launched powder and paste versions of Noroquin - its glucosamine-based supplement range - for horses.
Noroquin contains the active ingredients glucosamine, chondrotin sulphate, manganese sulphate, zinc sulphate, absorbic acid and N-Acetyl-D-Glucosamine, designed to maintain healthy cartilage, promote joint management and keep horses mobile.
Michelle Jones, Brand Manager at Norbrook said: "In recent years, horses are increasingly competing longer which means maintaining the longevity of the horse is vitally important for long term success. 60% of lameness is related to osteoarthritis and is regarded as the major cause of disability in the athletic horse.
"With increasing reliability on nutritional supplements and concerns from horse owners about their aging horse, our Noroquin for Horses range can be offered as alternative to traditional pain management products indicated for musculoskeletal ailments or alongside them as a completely safe addition to a joint management programme."
Michelle added: "The Noroquin paste for horses is a highly palatable apple flavored paste that can be fed directly to the horse as a tasty treat and offers an alternative to traditional methods while the Noroquin powder for Horses is a highly palatable powder that can be mixed with food. The product is available in handy single-use sachets for accurate dosing and waterproof 1kg tubs."
Noroquin Powder and Paste for Horses joins the newly launched tasty tablets for dogs and cats and powder for cats in the Noroquin range. It is available from wholesalers.
The University of Bristol's Langford Veterinary Services (LVS) has announced the completion of its new clinical facilities.
The first phase of the £13 million development includes a new small animal surgery building, comprising five theatres, an ICU, a dedicated anaesthesia induction and recovery and an imaging suite.
The imaging suite comprises a 16-slice CT scanner, for small animals and horses, conventional digital radiography with a DR system, a high-resolution fluoroscopy, diagnostic ultrasound, echocardiography, scintigraphy and a high resolution 1.5 tesla MRI scanner available seven days a week.
Lynne Hill, Chief Executive of LVS, said: "The new facility provides state-of-the art diagnostic imaging facilities at all times, to help the animals under our care."
LVS highlights the case of Gainsborough, an eight-year-old Irish draught gelding, to illustrate the benefits of its new facilities. The horse, used for jumping and endurance, was initially presented to the Equine Hospital in October 2010, with clinical signs including nasal airflow obstruction and discharge, which was limiting his athletic capabilities.
Using videoendoscopy and radiography, a space-occupying mass was diagnosed in the paranasal sinuses impinging into the nasal cavity. With the horse conscious, but sedated, using regional local anaesthetic nerve blocks, the bulk of the mass was removed and he returned to work. However, the owner reported a recurrence of the clinical signs and he was returned to the clinic for reassessment.
The new imaging suite, only one of a few such units in the UK, has been adapted to enable the imaging of a horse's head while conscious using a frictionless air plinth. The adaptation allows detailed imaging of both bone and soft tissue structures within a horse's head, without requiring a general anaesthetic.
Using the new imaging suite, Gainsborough's CT examination revealed a portion of the mass, which had been inaccessible to the previous keyhole surgery, had expanded into the nasal cavity. The detail of the images enabled careful planning of a second operation that facilitated removal of the large remnant of the mass, which appeared to be benign, with minimal collateral trauma.
In addition to imaging the heads of conscious horses, dogs and cats are able to undergo complete body scans using the same unit while anaesthetised. As well as enabling detection and diagnosis of lesions without invasive or painful tests at an earlier stage, the unit will facilitate operative planning and add to the body of knowledge of disease pathogenesis.
For more information about LVS, visit: http://www.langfordvets.co.uk/
The RCVS Charitable Trust has made two 'Blue Sky' grants of £20,000 each for research into feline rotavirus and equine gut bacteria.
One award has been made to Allison German and Kenton Morgan at the University of Liverpool as a Richard Daubney Research Fellowship. This will enable research to be undertaken into the molecular epidemiology and zoonotic potential of feline rotavirus in UK cats.
Allison said: "Feline rotaviruses have been identified in diarrhoeic children in Japan, Italy, Israel and America, but because of limited funding options, there has been no systematic study of rotaviruses in cats, so the prevalence, risk factors and zoonotic potential are unknown. I am pleased that the Trust has recognised the importance of emerging infectious diseases in companion animals and their potential role in animal and human health."
By assessing faecal samples from cats within Cats Protection Adoption Centres in the UK, the study aims to discover the prevalence of rotavirus in this cat population and broadly identify the strains of feline rotavirus that are circulating, including looking for any with identity to human strains. The study will also determine whether the molecular epidemiology of rotavirus in the cat population enables understanding of the diversification and evolution of rotaviruses in people.
A second Blue Sky award of £20,000 has been made to Chris Proudman and Alistair Darby, also at the University of Liverpool, to research the role of gut bacteria in horse health and disease. Called Metagenomic Analytical Utilities for Equines (MANURE), the project will sequence DNA from microbes taken from horse intestines, and analyse the diversity, composition and abundance of the microbial populations. This is expected to improve veterinary understanding of the role of equine gut bacteria, and benefit horses and their owners. Tools being developed to characterise and investigate equine gut microbiota, and findings expected, such as the discovery of novel bacteria, should also be useful to other research.
RCVS Trust Director Cherry Bushell said: "As usual, the standard of applications was very good, although we do continue to receive a relatively high number of applications for projects that the assessors judge to be more 'surveys' than genuine blue sky research.
"In deciding which research to fund, a number of factors are taken into account, such as the quality and strength of the research team, the likelihood of success, and whether a genuine gap in knowledge has been identified. For example, the feline rotavirus research could have important findings in the longer term if it is found that there is genuine risk to human health, and also shows clear potential for further study. Similarly, the equine gut bacteria study is likely to increase considerably knowledge over the longer term and to attract funding from elsewhere for further research."
Kruuse has announced that it has become the exclusive UK and Ireland distributor for Pulse Veterinary Technologies LLC shockwave systems, including the Versatron, Versatron 4paws and Equitron.
Shockwave therapy, otherwise known as extracorporeal shock wave therapy (ESWT), uses a high-energy sound wave that rapidly increases pressure as it travels through tissue. It is a non-invasive modality used to stimulate healing particularly in ligament, tendon or boney structures.
Andrew Groom, Managing Director, Kruuse UK Ltd said: "This agreement widens the Kruuse equine and small animal capital equipment profile within the UK and Ireland; increasing the range of technologies available to the veterinary practitioner , whilst providing aftercare support of existing shockwave users".
Eric Goorno , Chief Executive Officer, Pulse Veterinary Technologies LLC said: "This exciting partnership will further enhance our presence within the veterinary industry and allow Kruuse UK to bring leading edge technology to its customers, building upon its strong relationships within veterinary practices".
A research project funded by The Horse Trust has found that various types of ocular tumours can be successfully treated with mitomycin C, a cytotoxic antibiotic isolated from a bacterium.
The research concludes that mitomycin C offers a safe and cost effective alternative to current treatment options such as surgery and radiation.
The research project was led by Fernando Malalana, while working as The Horse Trust's Clinical Scholar in Equine Internal Medicine at University of Liverpool. Fernando is now working as a Clinician Teacher in Equine Internal Medicine at the university.
Ocular tumours are more difficult to treat than tumours in other parts of the horse's body due to the risk of damaging the eye. In the study, Malalana investigated the use of mitomycin C in treating ocular squamous cell carcinoma, the most common ocular tumour in horses, and occular sarcoids, skin tumors that frequently affect the eyelids .
Mitomycin C is an antibiotic isolated from a bacterium, Streptomyces caespitosus. It is known to have cytotoxic effects and has been used to treat tumours in horses before, but only in combination with surgery.
Currently, the main method of treating ocular squamous cell carcinoma is by removing the tumour surgically or with radiation. Both treatments are costly and have a number of associated risks. There is also the risk of damage or scarring to the eye.
Fourteen horses with ocular squamous cell carcinoma, three of which were affected bilaterally, were included in the study. Mitomycin C was applied to the conjunctival sac of the affected eye; in some of the cases the treatment was combined with surgery. Malalana found that of the 8 eyes treated with mitomycin C alone, clinical resolution occurred in 6 cases. Of the 9 eyes treated with both surgery and mitomycin C, clinical resolution occurred in 7 cases.
Mitomycin C was also used to treat various types of sarcoids found in the eye. Currently, the most effective treatment for occular sarcoids is radioactive wire. However, radioactive wire treatment is not ideal as it is expensive, only offered in two locations in the UK, and has potential health risks to the vet applying the wire due to exposure to radioactivity.
Six horses and two donkeys with occular sarcoids, including one horse that was affected bilaterally, were treated with mitomycin C, which was injected directly into the tumour. Malalana found that of the nine nodular and fibroplastic occular sarcoids treated with the antibiotic, all were completely cleared. However, the vets did not have good results with verrucous sarcoids.
Malalana said: "The results of this research should offer hope to the owners of horses that have eye tumours. We have already been contacted by vets from across Europe to find out more information about this treatment and hope that it will be offered to more horses with occular tumours in the future".
Vets at the University of Liverpool are now testing the use of mitomycin C on other tumours that are difficult to treat surgically, including melanomas near the horse's anus. So far, two cases have been treated, but it is too early to tell whether treatment has been successful.
Malalana's research has been submitted to Veterinary Ophthalmology journal.
Dunlops has changed its name to Henry Schein Animal Health.
David Hinton, Managing Director said: "As we change our name to Henry Schein Animal Health, we also reaffirm our company's strong commitment to offer a comprehensive array of products and services to help animal health practitioners in the United Kingdom operate more efficient and successful practices, and provide the best quality patient care.
"We have a new name, but we have the same strong team, the same values, and the same dedication to providing excellent service to our customers."
Henry Schein Animal Health’s expanded offerings include VetLink and Thrive. VetLink is a new e-commerce web site system that enables veterinary surgeons to access the growing internet sector, allowing you to sell anything from pet prescriptions to accessories online, to be delivered to your customers’ homes by Henry Schein Animal Health. Thrive is a new veterinary business analysis service that integrates with practice management software to use a Key Performance Indicator based approach that provides insight into a your practice and identifies areas where you can enhance your business.
The British Veterinary Association has welcomed the European Commission's Action Plan on Antimicrobial resistance (AMR), launched yesterday on the eve of European Antibiotic Awareness Day.
The Action Plan sets out 12 actions:
However, the association has expressed concern that the Commission has given only qualified support for new antimicrobials for veterinary use. Carl Padgett, President of the BVA, said: "There is much to be applauded in this action plan. In particular the BVA supports the calls for more and better coordinated research, more responsible use of antimicrobials in human and veterinary medicine, and the development of diagnostic tools to quickly and accurately identify the right drug for the right bug.
"The use of antimicrobials in the treatment and control of animal diseases is essential and the BVA supports the strong messages in this plan. Any option for managing AMR must be firmly rooted in sound scientific assessment of the risk.
"While the report recognises the difficulties that have led to the hampering of research into new antimicrobials for veterinary use, we are concerned that there is only qualified support from the Commission for the development of these new medicines for animal use.
"Research into new antimicrobials should be supported in both human and veterinary medicine. We need to ensure the creation of a more predictable regulatory environment to encourage new products for animals to be brought to the market.
"Finally, while the BVA supports the need for a new regulatory framework any new regulations must not impede the ability of veterinary surgeons to prescribe and dispense medicines according to their clinical judgement."
Meanwhile, Jill Moss of the Bella Moss Foundation added her voice to those calling for responsible use of antibiotics, highlighting recent research from the Royal Veterinary College that has established a clear link between pets with MRSA infection and human hospital-associated MRSA. What is less widely recognised, she says, is that resistant bacteria can be passed from human to animal.
The charity is now calling on health and veterinary professionals to work together to achieve a reduction in resistant infections by raising awareness and promoting the responsible use of antibiotics.
A research project funded by equine charity The Horse Trust has found that 40% of horses suffered a traumatic injury within the past year.
Only 13% of injuries occurred during ridden exercise, while 62% occurred while the horse was turned out in the field.
The research, which has been accepted for publication by the Equine Veterinary Journal, was carried out by Rosie Owen, who is currently working as The Horse Trust's Clinical Scholar in Equine Orthopaedics at the University of Liverpool.
Rosie said: "This Horse Trust-funded research shows that horses get injured relatively frequently - much more often than you would expect. Interestingly, most of the injuries happen during turnout, rather than during ridden exercise."
The results were obtained through analysing the responses from 652 randomly selected horse owners from north-west England, Midlands and North Wales, all of whom had a horse aged 15 years or younger. Owners sought veterinary treatment for 47% of the injuries reported, while the remainder were treated by the owner or a friend, or required no treatment.
Rosie identified a number of factors that were associated with an increased risk of injury. For example, horses that had been owned for a shorter period of time were found to be significantly more at risk of injury. She says the increased risk may be due to aggression from other horses when a new horse is introduced to a field, but owners can take various steps to reduce the likelihood of injury: "It's worth trying to avoid regular changes in group composition. A new horse should be introduced to the group gradually, preferably by providing adjacent stabling initially. Protective boots may help as the lower limbs are most at risk of injury. Also, if possible, the other horses in the field should have their shoes taken off during the period of adjustment, so they are less able to injure the new horse."
Rosie also found that horses turned out within larger groups were at an increased risk of injury. This is probably due to there being a larger hierarchy with multiple horses competing for dominance. However, she found that the risk of injury reduced when additional feeding areas were provided in the field: "If you provide hay or haylage to horses in the field, it's worth including an additional feeding area to reduce competition for food."
Other interesting findings included the lower incidence of injury in cob and pony breeds, compared to other breeds. Horses used competitively also had a higher risk of injury, which may be due to the additional athletic demands placed on these horses, or due to the way these horses are managed. Horses trained using Parelli methods were also found to be at an increased risk of injury, but as the numbers in this group were small, more research is needed to confirm this.
Although most of the injuries recorded in the survey occurred during turnout, 11% occurred in the stable, with most of the injuries affecting the head or eye. Rosie says owners can easily reduce the risk of stable injury: "There are various simple steps that owners can take to reduce the risk of injury in the stable. Try to provide hay from the floor, instead of in a hay rack, and make sure there are no protruding nails, hooks or sharp edges in the stable."
Rosie said that it would be useful to conduct further research to understand how injuries occur during turnout: "A lot of injuries are reported during turnout, but we're uncertain about what happened. It would be useful to observe the behaviour of horses in the field to see whether it's competition for food, or another factor, that is responsible for the high rate of injuries among horses."
Jeanette Allen, Chief Executive of The Horse Trust, said: "We are pleased that the research we've funded has provided such useful statistics on the risks of injury for horses. We hope that horse owners will follow some of the tips that Rosie has suggested to reduce the risk of their horse being injured."
B&W Equine Group has opened a brand new, state-of-the-art equine clinic at Breadstone in Gloucestershire.
The new facility opened on 1 October 2011. It cost over £2.2 million and is, according to the company, one Europe’s most advanced diagnostic and surgical centres.
B&W Equine Group was created in 2008, following a merger between Willesley Equine Clinic and Bushy Equine Vets. The 23 vet practice has four local equine clinics in Breadstone, Cardiff, Failand and Willesley.
The new clinic, located on a four acre site at Breadstone, close to the M4 and M5 intersections, provides state-of-the-art diagnostics and advanced laboratory facilities. It houses the only equine MRI scanner in Wales and the South West, as well as a CT scanner and scintigraphy unit. Orthopaedic and colic theatres, adult and neonatal intensive care suites and separate isolation units have all been custom-designed and are supported by five examination rooms and two knock down boxes.
Clinical and referral services are led by RCVS and European Recognised Specialists in surgery, orthopaedics, diagnostic imaging and internal medicine and include gynaecological management of breeding mares and pre-season disease screening. The on-site laboratory is one of only 30 in the UK to be certified by the HBLB to test for CEM and EVA.
Ian Camm, BVSc CertEP MRCVS, Group Director, said: “We are all extremely excited about the new clinic but our day-to-day first opinion work remains a top priority. For all our local clients it’s very much a case of business as usual but the fact that we have invested in the latest portable equipment, including video endoscopes, digital radiography and ultrasound scanners, means we can undertake more specialist work at client’s yards, as and when needed.”
For further information, visit www.bwequinevets.co.uk.
The first steps have begun to find Petplan and The Veterinary Business Journal's Practice Manager of the Year for 2012.
Nominations are now being sought for the most accomplished UK practice managers and recommendations are welcome from any member of the veterinary team.
Three finalists will be chosen and the winner announced at the annual Petplan Veterinary Awards in April 2012.
Robin Fearon, editor of the Veterinary Business Journal, said: "It is a distinct pleasure to launch the awards programme each year knowing that at the end of it we will be able to announce another winning practice manager.
"These awards are so important in promoting the role and highlighting the crucial part that managers play in practice strategy and success - we can't wait to see your nominations."
Judges will assess candidates' applications and choose the three finalists based on their competency in areas such as staff development, financial strategy and marketing initiative.
Last year's winner Denise Coston is practice manager at Castle Veterinary Surgeons in County Durham. She said: "Winning this award has meant a lot to me because it makes you feel valued. I would say to anyone thinking of nominating their practice manager: 'just do it'.
"The role of practice manager varies in each practice and can be hard to quantify with specific measures, but it means a lot to celebrate someone getting it right. It is an excellent way to promote the role of practice manager and it is great to get recognition alongside vets and nurses."
This award is supported by the Society of Practising Veterinary Surgeons and the Veterinary Practice Management Association.
As well as a plaque commemorating their achievements, the winner will once more receive one year's free membership to the VPMA.
Nominations for this year's award close on 10 February 2012. Application packs are available from: Jackie Morrison, The Veterinary Business Journal, Olympus House, Werrington Centre, Peterborough PE4 6NA, or e-mail jackiemorrison@vbd.uk.com.
Alternatively visit www.vetsonline.com/ to download yours direct.
The Veterinary Marketing Association has announced details of a new award for public relations, open to veterinary practices and companies.
The VMA says this award is to recognise the value that media and public relations can add to the marketing mix. It will be awarded to the company or veterinary practice that has delivered the most innovative PR campaign during 2011, as judged by a panel of industry professionals.
Organiser Claire Edmunds said: "The VMA Awards has become a coveted event for those involved in the animal health industry to showcase their marketing achievements. A range of categories has evolved since the awards began over 20 years ago, for marketing, creative communication and new media campaigns. However, we felt that an award for PR was required to complete the marketing mix".
Jane Manning from award sponsor Splash Marketing & Communications said: "We felt it was time to give the opportunity for those involved in PR to obtain the recognition they deserve alongside their creative colleagues.
"An effective PR campaign can be a highly influential marketing tool, so it's great news that the VMA has added this new award category. We hope that companies and agencies serving the animal health sector will embrace this new opportunity to showcase their creativity and hard work".
The award is for the most innovative PR initiative published during the year. This can be a single 'one-off' event or article, or a sustained campaign over a given period. The winner and two highly commended entries will be awarded at the VMA Awards on Friday 9th March 2012 at Shakespeare's UnderGlobe Theatre, London.
Further information on the awards and ticket application forms are available at the VMA's website - http://www.vma.org.uk/ or by calling 0844 561 6157. The deadline for entries is Friday 27th January 2012.
Vetoquinol has announced the launch of Equistro Flexadin UCII, an equine joint supplement.
Equistro Flexadin UCII contains a new ingredient, UC-II, which the company claims is one of the most effective and influential ingredients available that aids and supports healthy joint function.
To celebrate the launch of Flexadin UCII Vetoquinol is offering a £10 money off voucher available through purchases of Horse & Hound magazine starting from November 10th.
Caitríona Mullin, Equine Product Manager at Vetoquinol UK Ltd said: "We are very excited about the launch of Flexadin UCII in the UK and Ireland, we have already received excellent feedback from our German and French colleagues. Flexadin UCII is a product that will further enhance our premium range of equine supplements formulated specifically for the performance horse."
A research project funded by equine charity The Horse Trust has found that lameness is the most common reason for euthanasing a geriatric horse.
According to the charity, this research is the first in the UK to provide data on the causes of death in geriatric horses. Although post-mortem studies have provided some data regarding causes of death, "old age" was previously reported as a common reason for the euthanasia of adult horses.
The research was carried out by Joanne Ireland at the University of Liverpool and led by Dr Gina Pinchbeck. Ireland surveyed horse owners living in the North-West and Midlands areas of England and North Wales who have a horse aged 15 years or older. 918 owners of geriatric horses were followed in a cohort study and 118 mortalities were reported during the 18 month follow-up period, of which 111 were euthanased.
The researchers found that 24% of horses were euthanased due to lameness; an additional 12% were euthanased due to laminitis - a common cause of lameness. After lameness, colic was the next most common cause of euthanasia, with 21% of owners citing this as the main reason.
In an earlier stage of the project, the researchers had found that half the geriatric horses surveyed suffered from lameness, but only 24% of owners reported the problem.
Dr Pinchbeck said: "Although lameness is common in older horses, this is the first study to quantify its contribution to their mortality.
"Owners are often missing the early signs of lameness in their horse, which means the condition isn't being managed and may deteriorate faster."
Dr Pinchbeck said it would be useful to carry out further research into lameness in geriatric horses to find out the main causes of lameness and how these may be prevented or treated.
The research team also found that half of the horses euthanased were suffering from concurrent health problems and these influenced the owner's decision to euthanase in 43% of cases. The most frequently reported additional health problems were musculoskeletal problems, such as arthritis.
The mortality rate among the horses surveyed was 11 per 100 horse-years at risk, meaning that if 100 geriatric horses were followed for a year, an average of 11 would die. The mortality rate for horses over 30 years of age was over five times the rate than in horses aged 15 - 19 years.
Jeanette Allen, Chief Executive of The Horse Trust, said the data provided by this research is likely to provide useful information for both horse owners and vets to enable them to improve the welfare of older horses. She said: "As there are a significant number of geriatric horses in the UK, it is vital that we understand more about the health problems that affect them. We hope that more owners of older horses will give their horse an annual health-check to enable the horse to have a longer, healthier life."
The research was published in the September 2011 issue of Preventive Veterinary Medicine.
Merial Animal Health is inviting practitioners to submit original clinical pain management cases for The Previcox & Equioxx European Clinical Case Award for Excellence.
Set up last year, the award recognises excellence in pain management in companion animals and horses. Submitted cases will be evaluated for successful management of pain associated with osteoarthritis, surgery or other conditions in companion animals and horses using firocoxib.
Two winners will be selected and each awarded €1,000 and an invitation to present their clinical case during Merial's next European Pain Management Symposium in 2012, with all travel and accommodation expenses paid.
Open to all veterinary practitioners, the deadline for submission is December 1st 2011. For an application form please email agate.vanopstal@merial.com
Pfizer is giving away a free equine weigh tape with every purchase of Equest & Equest Pramox (while stocks last), to help encourage accurate treatment against encysted small redworms this season.
According to the company, Equest & Equest Pramox are the only wormers in the UK that treat encysted small redworm in a single dose. Using a weigh tape to work out their horse's weight will help your clients avoid under dosing, which increases the risk of resistance development.
Pfizer says small redworms are the most common worms found in horses today. They can pose a very serious health risk to horses and it's important for owners to make sure that they are treated properly during the autumn or early winter.
Small redworms can grow up to 2.5cm in length and are thin and reddish in colour. Small redworm eggs are passed in the faeces and then hatch on pasture and continue to develop into more advanced larval stages before being ingested by the horse as it grazes. The larvae burrow deeply into the wall of the gut where they encyst and may account for up to 90% of the redworm burden in the horse1. Encysted small redworm will not show up in a Faecal Worm Egg Count - even if the horse has shown a negative or low count it could still be harbouring several million encysted small redworms2.
Encysted small redworms can remain dormant inside a horse for up to two years, but they usually 'wake-up' in late winter or early spring, developing and emerging from the gut wall all at the same time. In severe infestations mass emergence can lead to a disease syndrome known as 'larval cyathostominosis', causing diarrhoea and colic with up to a 50% mortality rate3. Young horses of less than six years of age can often be at higher risk of the disease3 but small redworm can cause life-threatening illness at any time of year and in any age of horse.
Ben Gaskell, Pfizer's veterinary adviser said: "Treating encysted small redworms successfully in the late autumn or early winter is important to avoid the risk of larval cyathostominosis. It's important to advise your customers to choose a product that is licensed to treat the worms they are targeting and that they give the correct dose, by weighing their horse beforehand, as this will help preserve the efficacy of the drug used."
Pfizer's Does your wormer measure up campaign is backed with point of sale materials and a media campaign. To receive a free weigh tape, valued at £7 your clients need to buy a tube of Equest or Equest Pramox, fill in an application form and send Pfizer the batch and expiry flap from the pack. Pfizer will then send them a FREE Weigh Tape while stocks last.
For further information contact your Pfizer Account Manager.
References
1. Bairden K. et al (2001) Veterinary Record 148, 138-1412. Dowdall S.M.J. et al (2002) Veterinary Parasitology 106, 225‑2423. McWilliam H. et al (2010) International Journal for Parasitology 40, 265-275
WebLeC has launched a monthly online equine CPD service.
One hour live interactive sessions will take place every third Thursday at 7:30 pm. A single meeting costs £30 plus VAT, or savings can be made by taking out a flexible subscription that allows the user to choose any 12 meetings for the cost of 10 over a period of up to 24 months.
The next meeting is on 22nd September and is entitled: Colic Decision making: When to wake up the surgeon and what pain control to use. The presenter is Debra Archer form the University of Liverpool. Further details and registration links can be found at: http://www.ledstonequine.co.uk/weblec_lectures/colic.html
In addition, a recording of WebLeC's 6th meeting, which was held in partnership with BEVA and the VDS and dealt with the new guidelines and forms for pre-purchase examinations of horses, is now available to view free online at: www.bitly.com/weblecbevaPPE. Use the password: b3va to get access, and you will receive a CPD certificate if you fill in the registration form.
WebLeC has also been asked to host BEVA's online CPD and will be announcing further details of their meetings soon.
Elanco has announced the results of a challenge study which the company says demonstrates the ability of Duvaxyn IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Richmond/1/07 (H3N8) two weeks after a two dose primary course1.
The study, conducted by the Animal Health Trust, involved two groups of EIV seronegative horses. The first group, consisting of seven vaccinates, were given two dose of Duvaxyn IE-T Plus, 28 days apart, and challenged with A/equi-2/Richmond/1/07 (H3N8) virus strain 14 days after the second vaccination. The second group of unvaccinated horses was challenged at the same time. Duvaxyn IE-T Plus caused a statistically significant reduction in both clinical signs of the disease and in viral shedding.
According to Elanco, this is believed to be the first demonstration of cross protection by a current UK equine influenza vaccine against a Florida sub-lineage clade 2 reference strain.
The OIE (World Organisation for Animal Health) updated its equine influenza vaccine recommendations in 2010 to reflect the fact that all field strains characterised through 2008 and 2009 were of clade 1 or 2 of the Florida sub-lineage. The antigenic difference between viruses of these clades could potentially compromise the effectiveness of vaccines containing a representative of a single clade2.
Anna Jackson, national veterinary manager for Elanco Companion Animal Health, said: "Whilst no vaccine has been updated to match the current OIE recommendations, the results of this challenge study provide reassurance that horses vaccinated with Duvaxyn will be protected against clinical signs of disease caused by currently circulating strains of equine influenza, including those the OIE have identified as being of concern."
Duvaxyn IE-T Plus is an inactivated whole virus equine influenza vaccine, adjuvanted with an aqueous-based adjuvant. Elanco says that experts in the field of human vaccination have expressed the view that whole virus vaccines have the potential to induce a stronger and more broadly-based response to circulating influenza strains than those contained in sub-unit vaccines because of the presence of the full set of virus proteins in the vaccine3.
References:
Lanes Health, manufacturer of the mobility supplement, LitoVet, has announced the nominees for the inaugural Litovet Equine Scientific Achievement Award, part of the annual Animal Health Trust (AHT) awards.
The award which has been set up to recognise a person or group whose clinical or scientific work has made a substantial difference to the equine veterinary world will be judged by a panel of leading veterinary surgeons and scientists.
The nominees are:
Peter Clegg - MA VerMB PhD CertsES DepEVCS MRCVS. Dr Clegg is Professor of Equine Surgery and Deputy Head of the Institute of Ageing and Chronic Disease, Faculty of Health and Life Sciences, The University of Liverpool. Peter's current research focus is equine orthopaedics, in particular identifying the basic mechanisms of injury and repair in equine joints and tendons. He has supervised 13 successful PhD students and is currently supervising a further nine.
Andy Durham BSc, BVSc, DEIM, Dipl.ECEIM, MRCVS (RCVS & European Specialist in equine internal medicine). Liphook-based Andy Durham exemplifies the premise that veterinarians in practice can maintain an active interest in current research, undertake clinically relevant research projects, interact with researchers on an international stage and contribute to CPD through scientific papers, book chapters and lectures.
Tim Mair BVSc PhD DEIM DESTS DipECEIM MRCVS. Dr Mair ha been innovative in veterinary practice (e.g., an early adopter of standing magnetic resonance imaging [MRI]), has an extensive publication list recently focusing on evidence-based medicine for colic, but spanning the full breadth of common medical disorders in horses. He has made an enormous contribution to veterinary practice within both Europe and America in his role as Editor of Equine Veterinary Education.
Chris Proudman MA VetMB PhD CertEO FRCVS.Dr Proudman is Professor of Equine Studies at the University of Liverpool. His research interests are related to the aetiology and surgical management of acute intestinal disease (colic) in the horse: specifically, the diagnosis of intestinal parasites associated with colic and understanding dietary determinants of colic. Most recently this has involved using metabolomics and molecular microbiology to investigating the intestinal microbiota and its response to dietary change.
The LitoVet Equine Scientific Achievement Award can be granted to any individual or group that is currently undertaking, or has successfully implemented within the past ten years, one or more clinical or other research projects which has, or will, make a significant contribution to equine health and welfare.
The award will be presented to the recipient, or recipients, at the UK Equestrian Awards held at the Lancaster London on Thursday 3 November 2011.
The Veterinary Development Council (VDC) is conducting a survey to investigate the role of paraprofessionals and technicians in veterinary practice, and is asking vets in large animal, equine, and mixed practices to complete a short survey.
The VDC says that information from the survey will help inform discussions on the regulation of technicians.
The survey will take between 5 and 10 minutes to complete and can be found on the BVA website at www.bva.co.uk/vdc. The BVA has also emailed the survey directly to practices.
The survey has been devised by the VDC working group looking at the role of the veterinary-led team, chaired by BVA Past President Professor Bill Reilly. This is one of three working groups that will report to the VDC:
Professor Reilly said: "The relationship between veterinary surgeons and technicians is vital but it varies from practice to practice.
"The working group on the role of the veterinary-led team aims to take a snapshot of how services, such as artificial insemination and foot trimming, are currently delivered, and gauge how veterinary surgeons feel about other services being delivered by non-veterinarians in the future.
"I hope veterinary surgeons in large, mixed and equine practice will take 10 minutes to complete our survey to help us map the current use of technicians in veterinary practice and help shape our future discussions."
Boehringer Ingelheim VetMedica has published its equine endocrine webinars online for veterinary professionals to view on demand at www.prascend.co.uk/webinars.
The webinars, which cover 'Diagnostic challenges in equine endocrine disease', presented by equine internal medicine specialist Andy Durham from the Liphook Equine Hospital, and 'A problem-based approach to equine laminitis', presented by equine internal medicine specialist Dr Catherine McGowan from the University of Liverpool, are each one hour long.
Participants will each receive CPD certificates for participation.
Dechra Veterinary Products has launched Celox Veterinary, a product which stops arterial or venous haemorrhage within 3 minutes, described as 'revolutionary' by the company.
Celox Veterinary is available in both a granule formulation and in two sizes of gauze. The granules can be poured into a wound. Once pressure is applied, a clot forms and arterial and venous haemorrhage is stopped within three minutes, independent of the body's normal clotting processes. Celox Veterinary Gauze has the granules ready bonded onto its surface for ease of use.
Dechra says the product works by bonding with red blood cells and gelling with fluids to produce a robust clot which sticks to moist tissue to plug the bleeding site. It can be helpful in treating a wide range of veterinary cases including:
Celox Veterinary is made from chitosan, a natural polysaccharide and by-product of the shrimp industry. It generates no heat while in use and small amounts of residual material left in the body are naturally metabolised.
Dechra Product Manager Rachel Horton said: "Wound care is an area in which Dechra is known for its innovative product range. We are delighted to take this to the next level by offering this revolutionary treatment to vets and believe it will soon establish itself as an efficacious tool when they are faced with significant injuries and severe bleeding."
For further information on Celox Veterinary, please contact your Territory Manager or call Dechra direct on (01939) 211200.
Boehringer Ingelheim Vetmedica, manufacturer of the equine pergolide Prascend, has joined forces with the British Horse Society, Redwings Horse Sanctuary and World Horse Welfare to launch the 'Talk About Cushing's (TAC)' campaign.
The initiative, which will take place throughout September and October 2011, is aimed at raising awareness of Cushing's Disease and its clinical signs, perhaps the most familiar of which is hirsutism (abnormal hair growth, or delayed shedding). Horse owners can download a £15 money-off voucher from http://www.talkaboutcushings.co.uk/ throughout the TAC initiative, which can be redeemed through their veterinary practice against blood test costs.
Boehringer says Equine Cushing's Disease, also known as Pituitary Pars Intermedia Dysfunction (PPID), is the most common endocrine disorder in older horses and ponies1 ,and that some estimates suggest over 15% of horses and ponies over 15 years of age are affected2.
Unfortunately, the initial stages of Cushing's Disease are often difficult to detect, delaying the maximum benefit of early diagnosis and intervention. Blood testing is increasingly used to detect the disease and confirm diagnosis, however many horses with clinical signs, including recurrent laminitis, still go undiagnosed.
Craig Beck, vet and equine sales and marketing manager at Boehringer Ingelheim Vetmedica said: "More than 80% of horses suffering from laminitis may have an underlying endocrine disorder, such as Cushing's Disease3.
"The TAC campaign will raise awareness of Cushing's Disease amongst both veterinary professionals and owners. It should make it easier for vets to go ahead with endocrine testing in horses and ponies with recurrent laminitis, diagnosing and treating earlier in the course of the disease."
Lee Hackett, head of welfare at the BHS, added: "Cushing's Disease is relatively common in horses yet in our experience it frequently goes undiagnosed and untreated. This is why we are fully behind the 'Talk About Cushing's' campaign - anything that raises awareness and understanding of this disease has to be of benefit to equine welfare."
Redwings' head of veterinary services Nicky Jarvis said: "At Redwings we have many horses over the age of 15, all living very happy and healthy lives. 'Old age' is not in itself a disease so when a geriatric horse loses condition or appears unwell there is always an underlying cause. If a horse continually succumbs to laminitis or loses weight, Cushing's Disease could be one explanation. However, with early diagnosis, good management and the correct treatment a horse with Cushing's can live comfortably for many years."
"Early diagnosis of Cushing's Disease can be of great benefit, other conditions such as laminitis are often associated with it and it is important that clinical signs are recognised and treated appropriately. World Horse Welfare supports the 'Talk About Cushing's' campaign as it will help people to recognise the signs and take the right action to prevent horses from suffering," concludes Tony Tyler, deputy chief executive, World Horse Welfare.
Backed by an advertising and PR campaign in the equine consumer media, Boehringer Ingelheim Vetmedica has produced a marketing pack for veterinary practices to use in the run up to, and during TAC. This includes leaflets, invoice stickers, a veterinary practice toolkit featuring an owner evening presentation, editorial copy for newsletters and websites and images to support the campaign.
For further information on TAC or Prascend, the first licensed product for the treatment of Cushing's Disease, please visit http://www.talkaboutcushings.co.uk/, contact your Boehringer Ingelheim Vetmedica territory manager or call 01344 746959.
1. Donaldson et al. “Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis”. JAVMA, Vol 224, No. 7, April 1, 20042. McGowan. “Diagnostic and Management Protocols for Equine Cushings Syndrome” In Practice, November/December 20033. McGowan. “Epidemiology and Clinical Perspectives of Endocrinopathic Laminitis”, BEVA Congress 2009
Kruuse UK has announced that it will be launching its new Android telemetric ECG system at BEVA 2011.
The original Televet 100 supports transmission of ECG data to a range of approx 100m (330ft), allowing recording and displaying of real time data only within a confined lunging or riding arena. By linking this system to a mobile network via 3G Android phone and a Windows 7 based tablet PC, the new Televet system overcomes this range limitation.
The new system requires the rider/horse to carry a 3G mobile phone which transmits data over the mobile internet, allowing the veterinary surgeon to display and record real time data on any PC/laptop with internet access or mobile internet connection. This also includes GPS information collected by the phone allowing the ECG, heart rate and velocity of the horse to be displayed in parallel.
The Android Telemetric ECG system is specifically targeted towards veterinary applications in the field of sports horses where extended range is particularly useful, such as endurance riding, three day eventing and racing.
Televet software can now also be integrated in Dicom infrastructures in practice for data capture and recording.
Sarah Stokes, Kruuse Equine Territory Manager said: "the flexibility and simplicity of the system along with immediate access to ECG data of patients will be an invaluable diagnostic tool for UK vets allowing vital support for patients and owners wherever they are."
Visitors to the Kruuse stand at BEVA 2011 will also have the chance to win an Acer ICONI W500 tablet worth £500.
A research project funded by The Horse Trust has made important discoveries about how two peptides regulate the inflammatory response in horses. This knowledge could help with the development of improved anti-inflammatory drugs, which are used to treat a wide range of conditions in horses.
The research project was led by Professor Fiona Cunningham at the Royal Veterinary College in Hertfordshire and Dr Karen Rickards at the Donkey Sanctuary in Sidmouth, assisted by Dr Andrew Brooks at the RVC, and by Dr Kirstie Pickles, now at the Royal (Dick) School of Veterinary Studies in Edinburgh.
Inflammation is associated with a wide range of equine diseases, including recurrent airway obstruction, laminitis and sweet itch. Anti-inflammatory drugs, such as glucocorticosteroids, mainly work by blocking the formation and/or actions of compounds produced in the horse's body that cause inflammatory responses. However, these drugs are not always effective and can have unwanted side effects.
This research, funded by The Horse Trust, aimed to find out more about two naturally-occurring peptides - chains of amino acids that are shorter than proteins - known as annexin-1 and CXCL8. Both have been shown to affect the inflammatory response but little research has been done on their effects in horses. In the long term, knowing more about these compounds could help in the development of new anti-inflammatory drugs with fewer side effects.
During inflammation, neutrophils (a type of white blood cell) stick to the cells lining blood vessels and migrate into inflamed tissue, where they ingest and break down harmful agents. Using techniques that mimic these events, CXCL8 was found to cause adherence and migration of horse neutrophils. However, when it was used in combination with another pro-inflammatory substance, neutrophil migration and adherence were markedly decreased. This suggests that attempts to reduce inflammation by blocking the actions of CXCL8 might not be as beneficial as had been thought.
At the start of the project, the researchers had no information about horse annexin-1, other than its gene sequence, so their first step was to develop a method to detect the peptide in white blood cells. They established that it was present and, as horse annexin-1 has not yet been synthesised, they used a synthetic peptide derived from annexin-1, Ac2-26, to look at the effects on horse neutrophils.
They found that Ac2-26 decreased neutrophil adherence and migration in response to other pro-inflammatory compounds, although at high concentrations the peptide itself caused some cell activation, thereby increasing inflammation. They also found that dexamethasone (a glucocorticosteroid) increased the levels of annexin-1 in cells, indicating that, as in humans, this class of drugs is likely to act in part through the formation of annexin-1.
These findings suggest that the use of compounds which mimic the actions of annexin-1 may have limitations as anti-inflammatory drugs. As glucocorticosteroids partly work by forming annexin-1, further research is needed in order to find out how annexin-1 will act in the horse's body and establish how its formation contributes to the beneficial effects of these drugs.
Professor Cunningham said: "This Horse Trust-funded research has resulted in some very interesting findings about how inflammatory cells are regulated in horses. The receptors that annexin-1 and CXCL8 act upon could be targets for new equine inflammatory drugs, but more research is needed first to fully understand their actions and how they produce these effects."
The team's research has been accepted for publication by the journal Veterinary Immunology & Immunopathology.
Kruuse is to launch a new Manuka honey dressing at BEVA 2011 in September.
Kruuse says that honey has been used as a topical anti-microbial agent and dressing for over 2000 years, and that honey derived from the nectar of the Manuka tree (Leptospermum scoparium) has its own unique chemical properties. Manuka honey contains glucose oxidase imparted by the bees during its collection and storage. This enzyme facilitates low level release of hydrogen peroxide when in the presence of wound exudates and thus supports cellular proliferation and metabolism through an antioxidant effect. The high sugar and low pH content creates a high osmotic potential which gives honey excellent debridement and anti-inflammatory properties.
The company says that one of the biggest difficulties with the use of honey in wound dressings is ensuring that once applied it stays over the wound area. Many attempts to coat dressings have been unsuccessful; often the active honey ingredient is left within the packaging severely reducing the effectiveness of the dressing. Kruuse says its Manuka dressings have the active honey impregnated 'within' the dressing, which ensures precise and easy application even if wearing surgical gloves.
The Kruuse Manuka dressings range comes in impregnated adherent (Kruuse Manuka AD), non-adherent dressing (Kruuse Manuka ND) and 15g tube of Manuka G. Each dressing comes in 3 sizes 5x5 cm , 10x12.5 cm and the KRUUSE Manuka roll (10x100 cm) a unique product ideal for large vertical wounds. E.G. Equine forelimb.
Kruuse also says that the antimicrobial potency in Manuka honey is rated by a standardised rating known as Unique Manuka Factor (UMF). The higher the UMF the better the antimicrobial effect. A minimum UMF of 10 is required to ensure sufficient effect in the wound environment, Kruuse Manuka Honey Wound Dressings have a Unique Manuka Factor of 15.
There is a restricted annual supply of Manuka honey as this unique product supply is controlled by a small number of producers in New Zealand. Many current honey products available use blends of Manuka honey with other poorer quality honey, these are often less effective. Kruuse Manuka uses 100% Manuka honey in all its dressings with the profits of the sale being returned directly to the Maori tribe that oversee the production of Manuka honey.
Andrew Groom, Managing Director Kruuse UK Ltd. said: "I am very excited that we have been able to secure a direct connection to supply this unique product with the knowledge that the Maori suppliers will see the returns for generations to come whilst this new range of dressing will add huge versatility for day to day wound management!"